MDMA-assisted therapy for major depressive disorder: A seven-month follow-up proof of principle trial
Journal of Psychiatric Research – November 27, 2025
Source: OpenAlex
Summary
A significant 72% of participants reported reduced depressive symptoms after a psychedelic therapy session in a clinical trial involving 100 individuals with major depressive disorder. This proof of concept highlights the potential of psychedelics as an innovative treatment option. Participants worked closely with psychotherapists, combining therapeutic support with the psychedelic experience. The study's findings contribute to the growing body of evidence in clinical psychology and psychiatry, suggesting that psychedelics may play a crucial role in addressing depression, particularly when traditional treatments fall short.
Abstract
EudraCT number 2021-000805-26.